ClinicalTrials.gg
RecruitingNCT07049276MSLT-3Updated Jun 29, 2026

The Multicentre Selective Lymphadenectomy Trial - 3

An interventional study of Index lymph node resection and Therapeutic lymph node dissection in Cutaneous Melanoma, Stage III, sponsored by Melanoma Institute Australia. Recruiting at 8 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-29.

Sponsored by Melanoma Institute Australia · Not applicable, Interventional, and Other

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,500
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Melanoma by Melanoma Institute Australia — 5 open to participants now, 9 under way, none of them phase 3. Melanoma · Melanoma Institute Australia.

Planned enrollment
Largest of 12
1,500 · median 68
Started
2025
with 1 other
No phase
Only one
of the 13
Registered
13th of 13
by date

Among the 13 studies in Melanoma by Melanoma Institute Australia, this one has the largest planned enrollment of the 12 interventional ones that give a count, is one of 2 that started in 2025, is the only one with no phase, and was the 13th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 579 are open to participants now.

Browse Melanoma studies →

Open to participants now

5 of the 13 studies in Melanoma by Melanoma Institute Australia are open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Who these studies take

Of the 467 Melanoma studies recruiting now, 379 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Melanoma by Melanoma Institute Australia, or all of them as a file.
02

Study summary

The goal of this clinical trial is to demonstrate that there is no difference (non-inferiorty) in the 2 year recurrence-free survival (RFS) between 2 different surgical approaches for clinical Stage III melanoma. Following 6 weeks of standard neaodjuvant immunotherapy, patients will undergo either selective index lymph node resection (ILN) (identified at baseline as the largest affected lymph node) or the standard of care therapeutic lymph node dissection (TLND). The secondary aims are to assess if patients who are managed without TLND will have a reduction in surgical complications (less wound problems \& lymphoedema), an improved quality of life, at a lower healthcare utilisation.

Read the detailed description

The standard treatment under current guidelines for patients who have melanoma that has spread to the lymph nodes (Stage III disease) is a 'therapeutic lymph node dissection' or 'TLND'. This is the removal of all of the lymph nodes in the affected area, such as in the armpit, neck or groin. TLND surgery

Several clinical trials over the past 10 to 15 years have shown that treatment with immune system boosting drugs (known as immunotherapy) can help the body to better identify and attack the tumour cells. This is now used routinely for tumour that has spready beyond the lymph nodes (Stage IV disease) in melanoma and many other cancers.

When immunotherapy is given before TLND surgery (known as neoadjuvant therapy) the body can launch an increased immune response against the tumour cells to reduce or remove the amount of tumour before surgery. Neoadjuvant therapy for melanoma is typically given over 6 weeks before surgery. Patients may have further drug therapy and /or radiotherapy after TLND surgery to minimise the risk of recurrence.

At surgery after neoadjuvant immunotherapy, the removed lymph node tissue is examined by a pathologist who will then classify the amount of tumour cells left in the lymph nodes. Recent clinical trials have shown that 46-70% of patients have less than 10% of melanoma cells left in the lymph nodes. This is called a 'major pathological response' or 'MPR'. After 5 years, approximately 70% of patients having an MPR do not have a recurrence of melanoma. Neoadjuvant immunotherapy is now standard care for Stage III melanoma in Australia and other countries.

Both immunotherapy and TLND surgery have side effects. Some of these are of short duration and some last many months. Some of the side effects from immunotherapy include general nausea, diarrhoea, skin rash but also diabetes, thyroid or liver problems. Surgery may result in some pain, wound infection, wound breakdown, or short and long term lymphoedema - where fluid doesn't drain properly from the arms or legs, depending on where the original lymph node surgery was done.

A recent small clinical trial of 99 patients tested if patients who have neoadjuvant therapy can omit the need for TLND surgery, without changing the risk of recurrence. Patients in this study had the largest affected (index) lymph node marked with a clip under ultrasound or X-ray guidance before neoadjuvant therapy. After 6 weeks of neoadjuvant immunotherapy, the index lymph node was removed in a minor operation and the pathological response classified. Sixty-one percent of patients had an MPR and did not have any further surgery. After 2 years, 93% of these patients did not have a recurrence of melanoma. Patients without an MPR had TLND surgery and between 63 and 75% had no recurrence by 2 years.

This recent trial was too small to provide sufficient evidence for a change in standard treatment after neoadjuvant immunotherapy for patients having an MPR. We therefore plan to conduct a trial that is large enough to test if the new approach of index lymph node resection is not worse than the current standard care with TLND as measured by the number of people without melanoma recurrence within 2 years. This type of trial is known as a 'non-inferiority' trial. If index node resection is no worse than TLND, we also need to assess if there is a difference in the side effects or each type of surgery and in the quality of life experienced by patients. We also need to examine if there is any difference in the costs to patients and to the healthcare system for either surgery and the long term outcomes.

This is a randomised trial which means people are put into one of two groups by chance (randomly, or like tossing a coin). For patients who have an MPR to neoadjuvant therapy, half will have index lymph node removal with no further surgery and half the current standard of TLND surgery. Patients who do not have an MPR will have the standard TLND. All patients will have regular appointments with their surgeon to check for signs if the melanoma has returned and the study team will follow progress for up to 10 years.

03

Conditions studied

  • Cutaneous Melanoma, Stage III

Browse trials for

Keywords

  • Neoadjuvant
  • Non-inferiority
  • Randomised controlled trial
  • Adverse events
  • Quality of life
  • Healthcare economics
  • Index lymph node resection
  • Therapeutic lymph node dissection
  • Surgical morbidity
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female patients ≥ 18 years of age at the time of consent
  2. Written
  3. or histologically confirmed, resectable pathological Stage IIIB, C or D (Any T, N1b, N2b, N2c, N3b, or N3c) cutaneous or unknown primary melanoma, with or without primary tumour in situ
  4. A minimum of one macroscopic lymph node, defined as:

    • A palpable node, confirmed by pathology
    • A non-palpable node, but enlarged per 1.1 criteria (≥ 15 mm in shortest diameter) and confirmed by pathology
    • An ultrasound or PET/CT scan positive lymph node of any size, confirmed by pathology.
  5. Up to 3 satellite (defined as any foci of clinically evident cutaneous and/or subcutaneous occurring within 2 cm of but discontinuous from the primary melanoma) or in-transit metastases (defined as clinically evident cutaneous and/or subcutaneous metastases occurring >2 cm from the primary melanoma in the region between the primary and the regional lymph node basin) are permitted if they are completely resectable.
  6. Lymph node involvement in the groin (iliac, inguinal or both), axilla or neck only and may be unilateral or bilateral. Concurrent popliteal, epitrochlear or triangular intermuscular space (TIS) nodes permitted, as long as fully resectable.
  7. Tumour amenable to a newly obtained core of a lesion which has not been previously irradiated. Archival tissue from a past primary or nodal lesion (if applicable) or tissue taken for current diagnosis will also be collected if available.
  8. Systemic immunotherapy is scheduled for administration with at least one PD-(L)-1 check point inhibitor (e.g. nivolumab, pembrolizumab, cemiplimab). The immunotherapy regimen may include other (e.g. ipilimumab, relatlimab, fianlimab). The patient should meet the fitness for treatment requirements as detailed in the relevant regulatory-approved Product Information or Summary of Product Characteristics.
  9. Neoadjuvant course of treatment to be no longer than 6 weeks (allows for a maximum of 3 cycles at weeks 0, 3 and 6).
  10. (ECOG) performance status of 0-1.
  11. Anticipated of > 5 years.

Exclusion criteria

Exclusion Criteria:

  1. Uveal or mucosal melanoma.
  2. Isolated satellite or in-transit only (without any cytological or histological proven lymph node involvement).
  3. Involvement of any lymph node basin other than groin, axilla or neck. Concurrent popliteal, epitrochlear or triangular intermuscular space (TIS) nodes permitted, as long as fully resectable.
  4. Clinical or radiographic evidence of distant metastasis (any AJCC 8th ed M Stage).
  5. Previous history of lymph node surgery to the same nodal basin, that was more extensive than a sentinel lymph node (SLNB).
  6. Previous radiotherapy to the same nodal basin.
  7. Any to the administration of nivolumab, ipilimumab, pembrolizumab or relatlimab per regulatory-approved product information and / or medical oncologist.
  8. Prior , CTLA-4, PDL-1 or LAG 3 antibody exposure, or an agent directed to another stimulatory or co-inhibitory T-cell receptor for any disease or any chemotherapy or experimental local or systemic drug treatment.
  9. A plan to administer targeted therapy or any non-checkpoint inhibitor immunotherapy, or any intralesional therapy for melanoma in the setting.
  10. A plan to administer any experimental immunotherapy as part of a clinical trial in the neoadjuvant setting.
  11. Known additional (unless adequately treated) active within the previous 3 years, except for locally curable cancers that have been apparently cured. The following malignancies, if undergone successful definitive resection or curative treatment, are permitted:

    • Basal cell carcinoma of the skin
    • Squamous cell carcinoma of the skin
    • Carcinoma in situ (e.g. breast carcinoma, cervical cancer in situ, but excluding carcinoma in situ of the bladder) that have undergone potentially curative therapy
    • Prostatic intraepithelial neoplasia
    • In situ melanoma
    • Atypical melanocytic hyperplasia
    • Stage I melanoma
    • Other malignancies for which the patient has been disease free for 3 years, not requiring active anti-cancer therapy.
  12. An active disease or a requirement for chronic systemic therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of therapy within 14 days prior to the first dose of study treatment. The following are permitted:

    • Replacement therapy (e.g. thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc)
    • Inhaled or intranasal corticosteroids (with minimal systemic absorption) may be continued if patient is on a stable dose
    • Non-absorbed intra-articular steroid injections.
  13. Has had an allogenic tissue/solid organ transplant.
  14. Active (defined as Hepatitis B surface antigen [HBsAg] reactive) or virus (defined as HCV RNA [qualitative] is detected) infection. Note: no testing for Hepatitis B and Hepatitis C is required unless mandated by local health authority.
  15. Has a known history of (HIV). Note: no testing for HIV is required unless mandated by local health authority.
  16. Pregnant or breastfeeding females.
  17. Concurrent medical or social conditions that may prevent the patient from attending assessments or procedures per schedule.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,500 participants (estimated)

Study arms

  • Experimental
    Index Lymph Node

    The largest affected (index) lymph node marked with a clip under ultrasound or X-ray guidance and then removed after neoadjuvant therapy for the pathological response to be determined. The response then dictates the next step of management

    Procedure: Index lymph node resection

  • Active comparator
    Therapeutic lymph node dissection

    Complete removal of all nodes in the regional lymph node basin

    Procedure: Therapeutic lymph node dissection

Interventions

  • ProcedureIndex lymph node resection

    The largest lymph node affected with melanoma

  • ProcedureTherapeutic lymph node dissection

    Removal of all nodes in the melanoma affected lymph node basin

06

What researchers measure

Primary outcomes

  1. Recurrence free survival

    The proportion of patients with a major pathological response (MPR) alive and disease-free from the time of surgery to the end of 2 years follow up

    Time frame: 2 years

Secondary outcomes

  1. The rate of escalation to a therapeutic lymph node dissection (TLND) in the ILN arm due to isolated nodal recurrence in the ILN nodal basin

    Proportion of patients with a major pathological response (complete pathological response or near complete pathological response) in the index lymph node arm who have disease recurrence involving the same lymph node basin requiring complete dissection

    Time frame: 2 years

  2. The salvage rate with surgery, radiotherapy or new systemic therapy post operatively for disease recurrence in each surgical arm with a major pathological response (complete pathological response or near complete pathological response)

    Proportion of patients requiring any additional treatment for any disease recurrence following a complete or near complete pathological response

    Time frame: 2 years

  3. Distant metastasis free-survival

    Proportion of patients with distant metastases from randomisation to the date of first distant metastases diagnosis in each surgical arm, following a major pathological response (complete pathological response or near complete pathological response)

    Time frame: 2 years

  4. Overall survival

    Proportion of patients who die, from the date of randomisation to the date of death from any cause

    Time frame: 10 years

  5. Surgery-related adverse events

    Surgical related adverse events using CTCAE version 5.0

    Time frame: 2 years

  6. Surgery-related adverse events

    Surgical related adverse events using Clavien-Dindo scale

    Time frame: 3 weeks, 12 weeks and 48 weeks post surgery

  7. Patient-rated quality of life QLQ C30

    Baseline EUROQOL QLQ-C30,scores compared to scores reported over the duration on study

    Time frame: 6, 12, 24, 36 and 48 weeks

  8. Patient-rated quality of life EQ 5D5L

    Baseline EQ-5D-5L compared to scores reported over the duration on study

    Time frame: 6, 12, 24, 36 and 48 weeks

  9. Patient-rated quality of life FACT-M

    Week 6 FACT-M scores compared to scores reported over the duration on study

    Time frame: 6, 12, 24, 36 and 48 weeks

  10. Concordance of metabolic response with pathological response

    The PET results correlated with the pathological response

    Time frame: week 6

  11. Concordance of metabiolic response with RECIST response

    The PET results correlated with the CT response

    Time frame: week 6

  12. Concordance of metabolic response with circulating ctDNA

    The PET results correlated with the volume of circulating tumour DNA in the blood

    Time frame: week 6

  13. Health-related economic costs

    Comparison of the health-related costs related to each surgical procedure and its outcomes

    Time frame: 2 years

Other outcomes

  1. To identify prognostic and predictive biomarkers for recurrence

    Comparison of multi-omic biomarkers from baseline with clinical outcomes

    Time frame: 2 years

07

Study locations

4 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Aug 2030, 58 months after the start.

Of 220 non-industry interventional studies with no phase under Melanoma, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 62. This study's planned 58 months is above that.

Counting every sponsor, half of 228 studies reached it within 38 months; a quarter within 20 and three quarters within 62.

How these figures are worked out, and which studies are left out of them.

Registered
May 24, 2025
First posted
Jul 3, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Aug 2030
CompletionEst.
Aug 2040
Last update
Jun 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07049276
Lead sponsor
Melanoma Institute Australia
Responsible party
Sponsor
First posted
Jul 3, 2025
Start date
Oct 1, 2025
Primary completion
Aug 2030 (estimated)
Completion
Aug 2040 (estimated)
Last update
Jun 29, 2026

Study contacts

Alexander CJ van Akkooi
Contact
alexander.vanakkooi@melanoma.org.au
+612 9911 7200
Alexander CJ van Akkooi
study chair · Melanoma Institute Australia

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion